{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T06:17:07Z","timestamp":1780381027301,"version":"3.54.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The rising incidence of colorectal cancer (CRC) and the limited success of conventional therapies have spurred efforts to identify promising new drugs with fewer side effects. Dorema aucheri (DA) has shown potential as An Anti-cancer agent. Additionally, 5-fluorouracil (5-FU), a chemotherapy drug widely used for CRC. This study aims to investigate the effect of Liposome-encapsulated 5-FU and DA on tumor growth in a mouse model. The lipid thin-film hydration method was used to create the liposomes, and high-performance liquid chromatography (HPLC), dynamic light scattering (DLS), and transmission electron microscopy (TEM) were used to evaluate their characteristics. Using an MTT experiment, the impact on cell growth was assessed. BALB\/c mice were implanted with CT26 mouse tumor cells. Tumor growth was monitored by measuring tumor size. Real-time PCR was used to look at the levels of expression of VEGF, VEGF-R2, VE-Cadherin, VEGF-C, and \u03b2-actin genes in tumor tissue. The nanoparticles that were developed exhibited a spherical shape, uniform size, And An average diameter of  146\u2009\u00b1\u20094.6 nanometers. HPLC Analysis demonstrated that approximately 80% of the compound was successfully encapsulated within the nanoliposomes. The MTT assay results showed that the nanoliposome-encapsulated 5FU\u2009+\u2009DA (NLP\u2009+\u20095FU\u2009+\u2009DA) formulation resulted in a dose-dependent reduction in cell proliferation. The group treated with NLP\u2009+\u20095FU\u2009+\u2009DA exhibited the slowest tumor volume growth and the highest weight gain. Furthermore, the expression levels of VEGF, VEGF-R2, VE-Cadherin, and VEGF-C genes in the tumor microenvironment Comparing the NLP\u2009+\u20095FU\u2009+\u2009DA group to the control group revealed a substantial decrease. The combination of nanoliposomes loaded with 5-FU and DA can reduce the growth rate of colorectal tumors in mice. It can also reduce the expression of VEGF, VEGF-R2, VE-Cadherin, and VEGF-C genes.<\/jats:p>","DOI":"10.1038\/s41598-025-18676-6","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T13:43:31Z","timestamp":1759844611000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Nanoliposome loaded with 5-fluorouracil and Dorema aucheri extract reduces tumor growth in a mouse model of colorectal cancer"],"prefix":"10.1038","volume":"15","author":[{"given":"Fatemeh","family":"Keshavarz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firouzeh","family":"Nasimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Bardania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Soltanshahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamran","family":"Goudarzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erfan","family":"Azadifar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niloufar","family":"Mohamadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parisa","family":"Ramiyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghasem","family":"Ghalamfarsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"key":"18676_CR1","doi-asserted-by":"crossref","unstructured":"Siegel, R. L., Wagle, N. S., Cercek, A. & Smith, R. A. Jemal AJCacjfc. Colorectal cancer statistics, 2023;73(3):233\u2009\u2013\u200954. (2023).","DOI":"10.3322\/caac.21772"},{"key":"18676_CR2","doi-asserted-by":"crossref","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71(3), 209\u2013249 (2021).","DOI":"10.3322\/caac.21660"},{"key":"18676_CR3","doi-asserted-by":"crossref","unstructured":"Siegel, R. L. et al. Colorectal cancer statistics, 2017;67(3):177\u2009\u2013\u200993. (2017).","DOI":"10.3322\/caac.21395"},{"key":"18676_CR4","doi-asserted-by":"crossref","unstructured":"Skyrud, K. D. et al. How many deaths from colorectal cancer can be prevented by 2030? A scenario-based quantification of risk factor modification, screening, and treatment in Norway. Cancer Epidemiol. Biomarkers Prev. 26.9, 1420\u20131426 (2017).","DOI":"10.1158\/1055-9965.EPI-17-0265"},{"issue":"1","key":"18676_CR5","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s12902-019-0444-6","volume":"19","author":"G Soltani","year":"2019","unstructured":"Soltani, G. et al. Obesity, diabetes and the risk of colorectal adenoma and cancer. BMC Endocr. Disorders. 19 (1), 113 (2019).","journal-title":"BMC Endocr. Disorders"},{"key":"18676_CR6","doi-asserted-by":"crossref","unstructured":"Ji, H. et al. IL1A polymorphisms is a risk factor for colorectal cancer in Chinese Han population: a case control study. BMC cancer. 19, 1\u20138 (2019).","DOI":"10.1186\/s12885-019-5395-9"},{"key":"18676_CR7","doi-asserted-by":"crossref","unstructured":"Li, J-B. et al. Longitudinal associations between BMI change and the risks of colorectal cancer incidence, cancer-relate and all-cause mortality among 81,388 older adults: BMI change and the risks of colorectal cancer incidence and mortality. BMC cancer. 19, 1\u201313 (2019).","DOI":"10.1186\/s12885-019-6299-4"},{"key":"18676_CR8","unstructured":"Tian, Q. et al. THBS2 is a biomarker for AJCC stages and a strong prognostic indicator in colorectal cancer. J buon. 23.5, 1331\u20131336 (2018)."},{"key":"18676_CR9","doi-asserted-by":"crossref","unstructured":"Krasteva, N. & Georgieva, M. Promising therapeutic strategies for colorectal cancer treatment based on nanomaterials. Pharmaceutics. 14(6), 1213 (2022).","DOI":"10.3390\/pharmaceutics14061213"},{"key":"18676_CR10","doi-asserted-by":"crossref","unstructured":"Morawska, K. et al. 5-FU therapeutic drug monitoring as a valuable option to reduce toxicity in patients with Gastrointestinal cancer. Oncotarget. 9(14), 11559 (2018).","DOI":"10.18632\/oncotarget.24338"},{"key":"18676_CR11","doi-asserted-by":"crossref","unstructured":"Veenstra, C. M., Krauss, J. C. J. C. C. & Surgery, R. Emerging systemic therapies for colorectal cancer. Clinics in Colon and Rectal Surgery 31.03, 179\u2013191 (2018).","DOI":"10.1055\/s-0037-1602238"},{"key":"18676_CR12","doi-asserted-by":"crossref","unstructured":"Blondy, S. et al. 5-Fluorouracil resistance mechanisms in colorectal cancer: from classical pathways to promising processes. Cancer sci. 111.9, 3142\u20133154 (2020).","DOI":"10.1111\/cas.14532"},{"key":"18676_CR13","first-page":"107447","volume":"206","author":"S Vodenkova","year":"2020","unstructured":"Vodenkova, S. et al. 5-fluorouracil and other fluoropyrimidines in colorectal cancer. Past Present Future. 206, 107447 (2020).","journal-title":"Past Present Future"},{"key":"18676_CR14","unstructured":"Afshoon, E., Ostad Rahimi, A., Sadeghi, H., Afshoon, T. & Mahdavi, R. J. A. D. The effect of Dorema aucheri extract on breast tumor induced by DBMA in rats. Armaghane Danesh. 15.3, 224\u2013232 (2010)."},{"key":"18676_CR15","unstructured":"Mianabadi, M., Hoshani, M. & Salmanian SJJoAS Technology. Antimicrobial and Anti-oxidative effects of methanolic extract of Dorema aucheri Boiss. J. agric. sci. technol. 17(3), 623\u2013634 (2015)."},{"key":"18676_CR16","unstructured":"Mirzaei, A., Mirzaei, N. & Ghavamizadeh, M. J. L. S. J. Antioxidant activity and cytotoxicity of Dorema aucheri by artemia urmiana: a Brine shrimp lethality test. Armaghane Danesh. 10, 8\u201312 (2013)."},{"key":"18676_CR17","doi-asserted-by":"crossref","unstructured":"Nahvinejad, M., Pourrajab, F. & Hekmatimoghaddam, S. J. J. Extract of Dorema aucheri induces PPAR-\u03b3 for activating reactive oxygen species metabolism. J. Herb. Med. 6.4, 171\u2013179 (2016).","DOI":"10.1016\/j.hermed.2016.09.003"},{"key":"18676_CR18","doi-asserted-by":"crossref","unstructured":"Roghani, M., Baluchnejadmojarad, T., Vaez-Mahdavi, M. R., Roghani-Dehkordi & FJVp Mechanisms underlying quercetin-induced vasorelaxation in aorta of subchronic diabetic rats: an in vitro study. Vascular pharmacology. 42.1, 31\u201335 (2004).","DOI":"10.1016\/j.vph.2004.12.001"},{"issue":"13","key":"18676_CR19","doi-asserted-by":"publisher","first-page":"7470","DOI":"10.3390\/ijms25137470","volume":"25","author":"M Barathan","year":"2024","unstructured":"Barathan, M. et al. Innovative strategies to combat 5-Fluorouracil resistance in colorectal cancer: the role of phytochemicals and extracellular vesicles. Int. J. Mol. Sci. 25 (13), 7470 (2024).","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"18676_CR20","first-page":"2880","volume":"18","author":"JB Park","year":"2018","unstructured":"Park, J. B. et al. Corosolic acid reduces 5\u2013FU chemoresistance in human gastric cancer cells by activating AMPK. Mol. Med. Rep. 18 (3), 2880\u20132888 (2018).","journal-title":"Mol. Med. Rep."},{"key":"18676_CR21","doi-asserted-by":"publisher","first-page":"1348076","DOI":"10.3389\/fphar.2024.1348076","volume":"15","author":"J-Y Zou","year":"2024","unstructured":"Zou, J-Y. et al. Natural products reverse cancer multidrug resistance. Front. Pharmacol. 15, 1348076 (2024).","journal-title":"Front. Pharmacol."},{"issue":"1","key":"18676_CR22","doi-asserted-by":"publisher","first-page":"6635874","DOI":"10.1155\/2021\/6635874","volume":"2021","author":"R Dehghan","year":"2021","unstructured":"Dehghan, R., Bahreini, F., Najafi, R., Saidijam, M. & Amini, R. The combination of Zerumbone and 5-FU: A significant therapeutic strategy in sensitizing colorectal cancer cells to treatment. Biomed. Res. Int. 2021 (1), 6635874 (2021).","journal-title":"Biomed. Res. Int."},{"key":"18676_CR23","doi-asserted-by":"crossref","unstructured":"Li, R. et al. Morin inhibits the progression of 5-fluorouracil\u2013resistant colorectal cancer by suppressing autophagy. Int. J. Biochem. Cell Biol.  24, 106783 (2025).","DOI":"10.1016\/j.biocel.2025.106783"},{"key":"18676_CR24","first-page":"24","volume":"127","author":"R Sang","year":"2021","unstructured":"Sang, R., Stratton, B., Engel, A. & Deng, W. J. A. Liposome Technol. Towards Colorectal Cancer Ther. ;127:24\u201340. (2021).","journal-title":"Liposome Technol. Towards Colorectal Cancer Ther."},{"issue":"4","key":"18676_CR25","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.gendis.2022.02.007","volume":"10","author":"U Anand","year":"2023","unstructured":"Anand, U. et al. Cancer chemotherapy and beyond: current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis. 10 (4), 1367\u20131401 (2023).","journal-title":"Genes Dis."},{"issue":"4","key":"18676_CR26","doi-asserted-by":"publisher","first-page":"345","DOI":"10.31557\/apjcb.2023.8.4.345-350","volume":"8","author":"A Gorgzadeh","year":"2023","unstructured":"Gorgzadeh, A. et al. Investigating the properties and cytotoxicity of cisplatin-loaded nano-polybutylcyanoacrylate on breast cancer cells. Asian Pac. J. Cancer Biology. 8 (4), 345\u2013350 (2023).","journal-title":"Asian Pac. J. Cancer Biology"},{"key":"18676_CR27","doi-asserted-by":"crossref","unstructured":"Rideau, E., Dimova, R., Schwille, P. & Wurm, F. R. Landfester kjcsr. Liposomes and polymersomes: a comparative review towards cell mimicking. Chem Soc Rev. 47(23), 8572\u20138610 (2018).","DOI":"10.1039\/C8CS00162F"},{"key":"18676_CR28","doi-asserted-by":"crossref","unstructured":"Ghanbarikondori, P. et al. Enhancing cisplatin delivery via liposomal nanoparticles for oral cancer treatment. Indian J. Clin. Biochem. 40(2), 211\u2013217 (2024).","DOI":"10.1007\/s12291-024-01239-3"},{"key":"18676_CR29","doi-asserted-by":"publisher","first-page":"1535793","DOI":"10.3389\/fbioe.2025.1535793","volume":"13","author":"E Saberian","year":"2025","unstructured":"Saberian, E. et al. Bleomycin-loaded folic acid-conjugated nanoliposomes: a novel formulation for targeted treatment of oral cancer. Front. Bioeng. Biotechnol. 13, 1535793 (2025).","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"2","key":"18676_CR30","doi-asserted-by":"publisher","first-page":"155","DOI":"10.31557\/apjcb.2023.8.2.155-159","volume":"8","author":"F Mohammadinezhad","year":"2023","unstructured":"Mohammadinezhad, F. et al. Preparation, characterization and cytotoxic studies of cisplatin-containing nanoliposomes on breast cancer cell lines. Asian Pac. J. Cancer Biology. 8 (2), 155\u2013159 (2023).","journal-title":"Asian Pac. J. Cancer Biology"},{"issue":"5","key":"18676_CR31","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.pbj.2017.07.073","volume":"2","author":"ME Bayatpoor","year":"2017","unstructured":"Bayatpoor, M. E., Vani, J. R. & Mohammadi, M. T. Hydroalcoholic extract of Dorema aucheri leaves prevents weakening of the brain antioxidant defense system and inhibits oxidative damage in rat model of ischemic stroke: PS086. Porto Biomedical J. 2 (5), 205\u2013206 (2017).","journal-title":"Porto Biomedical J."},{"issue":"1","key":"18676_CR32","doi-asserted-by":"publisher","first-page":"1745877","DOI":"10.1049\/2023\/1745877","volume":"2023","author":"M Azizi","year":"2023","unstructured":"Azizi, M., Ghalamfarsa, G., Khosravani, F., Bardania, H. & Azizi, S. Nanoliposomal coencapsulation of Dorema aucheri extract and curcumin; enhanced cytotoxicity, apoptosis induction, and Inhibition of EGFR gene expression in oral cancer cells OCC-02. IET Nanobiotechnol. 2023 (1), 1745877 (2023).","journal-title":"IET Nanobiotechnol."},{"key":"18676_CR33","doi-asserted-by":"crossref","unstructured":"Hossiniyan, S. A. et al. Chemical composition and cytotoxic activity of the essential oil from the aerial parts of Dorema aucheri.  J Herbmed Pharmacol. 10.3, 344\u2013350 (2021).","DOI":"10.34172\/jhp.2021.40"},{"issue":"7","key":"18676_CR34","doi-asserted-by":"publisher","first-page":"5157","DOI":"10.1007\/s00210-024-02945-8","volume":"397","author":"F Keshavarz","year":"2024","unstructured":"Keshavarz, F. et al. Thymol-loaded liposomes effectively induced apoptosis and decreased EGFR expression in colorectal cancer cells. Naunyn. Schmiedebergs Arch. Pharmacol. 397 (7), 5157\u20135165 (2024).","journal-title":"Naunyn. Schmiedebergs Arch. Pharmacol."},{"issue":"1","key":"18676_CR35","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ymthe.2018.11.010","volume":"27","author":"G Shi","year":"2019","unstructured":"Shi, G. et al. Modulating the tumor microenvironment via oncolytic viruses and CSF-1R Inhibition synergistically enhances anti-PD-1 immunotherapy. Mol. Ther. 27 (1), 244\u2013260 (2019).","journal-title":"Mol. Ther."},{"issue":"11","key":"18676_CR36","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1038\/sj.bjc.6605642","volume":"102","author":"P Workman","year":"2010","unstructured":"Workman, P. et al. Guidelines for the welfare and use of animals in cancer research. Br. J. Cancer. 102 (11), 1555\u20131577 (2010).","journal-title":"Br. J. Cancer"},{"issue":"4","key":"18676_CR37","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.3892\/ol.2014.1856","volume":"7","author":"Z Cao","year":"2014","unstructured":"Cao, Z. et al. Antitumor and Immunomodulatory effects of low\u2013dose 5\u2013FU on hepatoma 22 tumor\u2013bearing mice. Oncol. Lett. 7 (4), 1260\u20131264 (2014).","journal-title":"Oncol. Lett."},{"key":"18676_CR38","doi-asserted-by":"crossref","unstructured":"Udofot, O. et al. Pharmacokinetic, biodistribution and therapeutic efficacy of 5-fluorouracil-loaded pH-sensitive pegylated liposomal nanoparticles in HCT-116 tumor bearing mouse. J. Nat. Sci. 2(1), e171 (2016).","DOI":"10.15761\/ICST.1000150"},{"key":"18676_CR39","doi-asserted-by":"crossref","unstructured":"Ohta, A. et al. A2A adenosine receptor protects tumors from antitumor T cells. Proceedings of the National Academy of Sciences. 103.35, 13132\u201313137 (2006).","DOI":"10.1073\/pnas.0605251103"},{"issue":"2","key":"18676_CR40","doi-asserted-by":"publisher","first-page":"e13684","DOI":"10.1016\/j.heliyon.2023.e13684","volume":"9","author":"M Ali","year":"2023","unstructured":"Ali, M., Wani, S. U. D., Salahuddin, M., S, N. M. & Dey, K. M. Recent advance of herbal medicines in cancer- a molecular approach. Heliyon 9 (2), e13684 (2023).","journal-title":"Heliyon"},{"issue":"1","key":"18676_CR41","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s12291-024-01279-9","volume":"40","author":"E Saberian","year":"2025","unstructured":"Saberian, E. et al. Combination therapy of Curcumin and cisplatin encapsulated in niosome nanoparticles for enhanced oral cancer treatment. Indian J. Clin. Biochem. 40 (1), 59\u201366 (2025).","journal-title":"Indian J. Clin. Biochem."},{"key":"18676_CR42","doi-asserted-by":"crossref","unstructured":"Etebari, M., Sajjadi, S. E., Jafarian-Dehkordi, A. & Nazmakanipour, S. J. A. Genotoxicity evaluation of hydroalcoholic and aqueous extracts of Dorema aucheri by the comet assay. Adv Biomed Res. 5(1), 199 (2016).","DOI":"10.4103\/2277-9175.190993"},{"key":"18676_CR43","doi-asserted-by":"crossref","unstructured":"Mosaddegh, M. et al. Ethnomedical survey and cytotoxic activity of medicinal plant extracts used in Kohgiluyeh and Boyerahmad Province in Iran. J. Herb. Spic. Med. Plants. 18.3, 211\u2013221 (2012).","DOI":"10.1080\/10496475.2012.671801"},{"key":"18676_CR44","doi-asserted-by":"crossref","unstructured":"Azizi, M., Ghalamfarsa, G., Khosravani, F., Bardania, H. & Azizi, S. J. I. N. Nanoliposomal Coencapsulation of Dorema aucheri Extract and Curcumin; Enhanced Cytotoxicity, Apoptosis Induction, and Inhibition of EGFR Gene Expression in Oral Cancer Cells OCC-02. ;2023. (2023).","DOI":"10.1049\/2023\/1745877"},{"key":"18676_CR45","unstructured":"Khoshvaght\u0131, A., Val\u0131zadeh, M., Vase\u0131, M., Naz\u0131f\u0131, S. & Akbarpour, B. J. \u0130. \u00dc. V. F. D. The effects of Dorema aucheri hydroalcoholic extract on blood levels of antioxidant enzymes (SOD and GPX) and vitamins (E and C) in vivo. \u0130stanbul \u00dcniversitesi Veteriner Fak\u00fcltesi Dergisi. 39.2, 230\u2013237 (2013)."},{"issue":"4","key":"18676_CR46","first-page":"378","volume":"15","author":"A Sharifi","year":"2011","unstructured":"Sharifi, A., Naghmachi, M. & Bahrami, S. J. A. Antimicrob. Activities Dorema Auchri ;15(4):378\u2013387. (2011).","journal-title":"Antimicrob. Activities Dorema Auchri"},{"key":"18676_CR47","doi-asserted-by":"crossref","unstructured":"Tal\u00e9ns-Visconti, R., D\u00edez-Sales, O., de Juli\u00e1n-Ortiz, J. V. & N\u00e1cher, A. Nanoliposomes in cancer therapy: marketed products and current clinical trials. Int. J. Mol. Sci. 23(8), 4249 (2022).","DOI":"10.3390\/ijms23084249"},{"key":"18676_CR48","doi-asserted-by":"crossref","unstructured":"Dewi, M. K., Chaerunisaa, A. Y., Muhaimin, M. & Joni, I. M. Improved activity of herbal medicines through nanotechnology. Nanomaterials (Basel Switzerland). 12(22), 4073 (2022).","DOI":"10.3390\/nano12224073"},{"issue":"9","key":"18676_CR49","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.31557\/APJCP.2023.24.9.3291","volume":"24","author":"ZAC Heidari","year":"2023","unstructured":"Heidari, Z. A. C. et al. Characteristics and cytotoxic effects of nano-liposomal Paclitaxel on gastric cancer cells. Asian Pac. J. Cancer Prevention: APJCP. 24 (9), 3291 (2023).","journal-title":"Asian Pac. J. Cancer Prevention: APJCP"},{"key":"18676_CR50","doi-asserted-by":"crossref","unstructured":"Sethy, C. & Kundu, C. N. J. B. Pharmacotherapy. 5-Fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: implication of DNA repair Inhibition. Biomed. pharmacother. 137, 111285 (2021).","DOI":"10.1016\/j.biopha.2021.111285"},{"key":"18676_CR51","doi-asserted-by":"crossref","unstructured":"Dupertuis, Y. M. et al. Antitumor effect of 5-fluorouracil-loaded liposomes containing n-3 polyunsaturated fatty acids in two different colorectal cancer cell lines. Aaps Pharmscitech. 22.1, 36 (2021).","DOI":"10.1208\/s12249-020-01897-5"},{"issue":"1","key":"18676_CR52","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1208\/s12249-020-01897-5","volume":"22","author":"YM Dupertuis","year":"2021","unstructured":"Dupertuis, Y. M. et al. Antitumor effect of 5-Fluorouracil-Loaded liposomes containing n-3 polyunsaturated fatty acids in two different colorectal cancer cell lines. AAPS PharmSciTech. 22 (1), 36 (2021).","journal-title":"AAPS PharmSciTech"},{"issue":"5","key":"18676_CR53","first-page":"4288","volume":"24","author":"NB Ndemazie","year":"2023","unstructured":"Ndemazie, N. B. et al. Evaluation of anticancer activity of zhubech, a new 5-FU analog liposomal formulation. Against Pancreat. Cancer. 24 (5), 4288 (2023).","journal-title":"Against Pancreat. Cancer"},{"issue":"4","key":"18676_CR54","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1111\/cas.14312","volume":"111","author":"L Luput","year":"2020","unstructured":"Luput, L. et al. Liposomal Simvastatin sensitizes C26 murine colon carcinoma to the antitumor effects of liposomal 5-fluorouracil in vivo. Cancer Sci. 111 (4), 1344\u20131356 (2020).","journal-title":"Cancer Sci."},{"key":"18676_CR55","doi-asserted-by":"crossref","unstructured":"Liu, Y. S. et al. Dual Drug-Loaded nanoliposomes encapsulating Curcumin and 5-Fluorouracil with advanced medicinal applications: Self-Monitoring and antitumor therapy. Molecules (Basel Switzerland). 28(11), 4353 (2023).","DOI":"10.3390\/molecules28114353"},{"issue":"Suppl1","key":"18676_CR56","first-page":"S47","volume":"13","author":"S Savabkar","year":"2020","unstructured":"Savabkar, S. et al. Lack of association between VEGF \u2013\u20092578\u00a0C\/A polymorphism and risk of colorectal cancer in an Iranian population. Gastroenterol. Hepatol. Bed Bench. 13 (Suppl1), S47\u2013s52 (2020).","journal-title":"Gastroenterol. Hepatol. Bed Bench"},{"key":"18676_CR57","doi-asserted-by":"crossref","unstructured":"Al-Joufi, F. A. et al. Molecular pathogenesis of colorectal cancer with an emphasis on recent advances in biomarkers, as well as Nanotechnology-Based diagnostic and therapeutic approaches. Nanomaterials (Basel Switzerland). 12(1), 169 (2022).","DOI":"10.3390\/nano12010169"},{"key":"18676_CR58","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Zhu, S. & Xu, X. Zuo LJJoo. In vitro study of combined application of bevacizumab and 5-fluorouracil or bevacizumab and mitomycin c to inhibit scar formation in glaucoma filtration surgery. ;2019. (2019).","DOI":"10.1155\/2019\/7419571"},{"key":"18676_CR59","unstructured":"Hoyama, E. et al. (eds) Expression of Vascular Endothelial Growth Factor (VEGF) in Macrophages, Fibroblasts, and Endothelial Cells in Pterygium Treated with 5-Fluorouracil (Taylor & Francis, 2015). Seminars in ophthalmology."},{"key":"18676_CR60","doi-asserted-by":"crossref","unstructured":"Liu, W. et al. Bevacizumab-enhanced antitumor effect of 5\u2010fluorouracil via upregulation of thymidine phosphorylase through vascular endothelial growth factor A\/vascular endothelial growth factor receptor 2\u2010specificity protein 1 pathway. ;109(10):3294\u2009\u2013\u2009304. (2018).","DOI":"10.1111\/cas.13779"},{"key":"18676_CR61","doi-asserted-by":"crossref","unstructured":"Itashiki, Y. et al. Antitumor effects of bevacizumab in combination with fluoropyrimidine drugs on human oral squamous cell carcinoma. Oncology Letters, 22.4, 730 (2021).","DOI":"10.3892\/ol.2021.12991"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18676-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18676-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18676-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T13:43:47Z","timestamp":1759844627000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18676-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["18676"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-18676-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,7]]},"assertion":[{"value":"30 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All authors approved this manuscript. No competing interests declared.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Under approval number IR.YUMS.REC.1400.023, the Ethics Committee of Yasuj University of Medical Sciences provided ethical approval for this investigation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"34895"}}